Company performance
Add to research
Current Price
as of Jun 18, 2025$9.32
P/E Ratio
N/A
Market Cap
$901.61M
Description
Add to research
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland.
Metrics
Add to research
Overview
- HQDublin, DU
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerAVDL
- Price$9.32-0.53%
Trading Information
- Market cap$901.61M
- Float91.35%
- Average Daily Volume (1m)1,690,180
- Average Daily Volume (3m)1,335,057
- EPS-$0.27
Company
- Revenue$194.45M
- Rev growth (1yr)93.21%
- Net income-$4.92M
- Gross margin89.38%
- EBITDA margin-4.14%
- EBITDA-$2.18M
- EV$728.31M
- EV/Revenue3.75
- P/EN/A
- P/S4.63
- P/B12.16
- Debt/Equity51.86
Documents
Add to research
SEC Filings
Factset Street Account
Earnings Calls
Factset